Wird geladen...
Changing R&D models in research-based pharmaceutical companies
New drugs serving unmet medical needs are one of the key value drivers of research-based pharmaceutical companies. The efficiency of research and development (R&D), defined as the successful approval and launch of new medicines (output) in the rate of the monetary investments required for R&...
Gespeichert in:
| Veröffentlicht in: | J Transl Med |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4847363/ https://ncbi.nlm.nih.gov/pubmed/27118048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0838-4 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|